Comparison of the Continuation Rates of Romosozumab and Teriparatide Administrations in a Rural Area.

IF 1.6 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Tohoku Journal of Experimental Medicine Pub Date : 2025-06-06 Epub Date: 2024-09-19 DOI:10.1620/tjem.2024.J102
Hiroyuki Tsuchie, Hidekazu Abe, Norimitsu Masutani, Naohisa Miyakoshi
{"title":"Comparison of the Continuation Rates of Romosozumab and Teriparatide Administrations in a Rural Area.","authors":"Hiroyuki Tsuchie, Hidekazu Abe, Norimitsu Masutani, Naohisa Miyakoshi","doi":"10.1620/tjem.2024.J102","DOIUrl":null,"url":null,"abstract":"<p><p>Romosozumab has a dual effect on bones; it promotes bone formation and inhibits bone resorption and has a strong bone density-increasing effect. There have been various reports on the continuation rates of teriparatide, another drug used for osteoporosis treatment; however, there are few reports on the continuation rate of romosozumab. Therefore, this study aimed to examine the continuation rate of romosozumab and the factors affecting it, and to compare the continuation rates of romosozumab and teriparatide in a rural area. We retrospectively reviewed 199 patients with osteoporosis who were administered romosozumab monthly and teriparatide acetate preparation weekly or twice-weekly in an outpatient clinic. Patient information included age, sex, distance by road to the hospital, reason for the start of treatment, history of osteoporosis treatment and fracture, serum levels of some parameters, bone mineral density, adverse events, and a continuation period within one year. We compared differences in patient backgrounds and continuation rates among the romosozumab (ROM), twice-weekly teriparatide (TW), and weekly teriparatide (W) groups. Furthermore, we examined the factors influencing discontinuation in all patients. The continuation rate of the ROM group (88.9%) was significantly higher than that of the W group (70.2%) (P = 0.0358). In the Kaplan-Meier curves for treatment continuation, the ROM group showed a significantly higher continuation rate than the W group (P = 0.0202). Univariate analyses of all patients showed that romosozumab administration reduced the risk of discontinuation (P = 0.0450). Romosozumab has a considerably higher continuation rate than weekly teriparatide.</p>","PeriodicalId":23187,"journal":{"name":"Tohoku Journal of Experimental Medicine","volume":" ","pages":"99-106"},"PeriodicalIF":1.6000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tohoku Journal of Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1620/tjem.2024.J102","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Romosozumab has a dual effect on bones; it promotes bone formation and inhibits bone resorption and has a strong bone density-increasing effect. There have been various reports on the continuation rates of teriparatide, another drug used for osteoporosis treatment; however, there are few reports on the continuation rate of romosozumab. Therefore, this study aimed to examine the continuation rate of romosozumab and the factors affecting it, and to compare the continuation rates of romosozumab and teriparatide in a rural area. We retrospectively reviewed 199 patients with osteoporosis who were administered romosozumab monthly and teriparatide acetate preparation weekly or twice-weekly in an outpatient clinic. Patient information included age, sex, distance by road to the hospital, reason for the start of treatment, history of osteoporosis treatment and fracture, serum levels of some parameters, bone mineral density, adverse events, and a continuation period within one year. We compared differences in patient backgrounds and continuation rates among the romosozumab (ROM), twice-weekly teriparatide (TW), and weekly teriparatide (W) groups. Furthermore, we examined the factors influencing discontinuation in all patients. The continuation rate of the ROM group (88.9%) was significantly higher than that of the W group (70.2%) (P = 0.0358). In the Kaplan-Meier curves for treatment continuation, the ROM group showed a significantly higher continuation rate than the W group (P = 0.0202). Univariate analyses of all patients showed that romosozumab administration reduced the risk of discontinuation (P = 0.0450). Romosozumab has a considerably higher continuation rate than weekly teriparatide.

罗莫司单抗和特立帕肽在农村地区持续用药率的比较
Romosozumab对骨骼有双重作用;它促进骨形成,抑制骨吸收,并有很强的增加骨密度的作用。关于特立帕肽(另一种用于治疗骨质疏松症的药物)的持续率有各种各样的报告;然而,很少有关于romosozumab持续率的报道。因此,本研究旨在考察罗莫单抗的持续率及其影响因素,并比较罗莫单抗与特立帕肽在农村地区的持续率。我们回顾性地回顾了199例骨质疏松症患者,这些患者每月在门诊接受罗莫索单抗治疗,每周或每周两次服用醋酸特立帕肽制剂。患者信息包括年龄、性别、到医院的道路距离、开始治疗的原因、骨质疏松症治疗和骨折史、一些参数的血清水平、骨密度、不良事件和一年内的持续时间。我们比较了romosozumab (ROM)、特立帕肽(TW)和特立帕肽(W)三组患者背景和延续率的差异。此外,我们检查了影响所有患者停药的因素。ROM组的延续率(88.9%)显著高于W组(70.2%)(P = 0.0358)。在Kaplan-Meier曲线中,ROM组治疗持续率显著高于W组(P = 0.0202)。所有患者的单因素分析显示,给予romosozumab可降低停药风险(P = 0.0450)。Romosozumab的延续率明显高于每周特立帕肽。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
4.50%
发文量
171
审稿时长
1 months
期刊介绍: Our mission is to publish peer-reviewed papers in all branches of medical sciences including basic medicine, social medicine, clinical medicine, nursing sciences and disaster-prevention science, and to present new information of exceptional novelty, importance and interest to a broad readership of the TJEM. The TJEM is open to original articles in all branches of medical sciences from authors throughout the world. The TJEM also covers the fields of disaster-prevention science, including earthquake archeology. Case reports, which advance significantly our knowledge on medical sciences or practice, are also accepted. Review articles, Letters to the Editor, Commentary, and News and Views will also be considered. In particular, the TJEM welcomes full papers requiring prompt publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信